Adial Pharmaceuticals (NASDAQ:ADIL) Issues Quarterly Earnings Results

Adial Pharmaceuticals (NASDAQ:ADIL) posted its quarterly earnings results on Tuesday. The company reported ($0.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.20), Zacks reports.

Adial Pharmaceuticals Price Performance

Adial Pharmaceuticals stock traded up $0.00 during trading hours on Thursday, reaching $0.97. The company had a trading volume of 166,381 shares, compared to its average volume of 3,723,688. Adial Pharmaceuticals has a 12-month low of $0.77 and a 12-month high of $4.46. The company has a 50-day moving average price of $1.12 and a 200 day moving average price of $1.40.

About Adial Pharmaceuticals

Adial Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder.